Argenx Reports Positive Phase 3 Data for VYVGART in Autoimmune Myositis
The Netherlands-based immunology company met its primary endpoint in the ALKIVIA trial, marking the first successful Phase 3 study in immune-mediated necrotizing myopathy.
Trial Meets Primary Endpoint
Argenx SE disclosed positive topline results from its ALKIVIA Phase 3 study evaluating VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis, according to a 6-K filing submitted August 17, 2026.
The study met its primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) patients, with a p-value of 0.0011 (6-K filing, 2026-08-17). Patients treated with efgartigimod demonstrated a statistically significant 15.4-point greater improvement versus placebo, with scores of 47.95 compared to 32.56 (6-K filing, 2026-08-17).
The company, which holds a market capitalization of approximately $53 billion with shares last closing at $730.20, scheduled a conference call for August 17 at 2:30 PM CET to discuss the results (MarginX data).
Breakthrough in IMNM Treatment
The filing highlighted that this represents "the first Phase 3 study to show statistically significant and clinically meaningful improvements in disease activity in IMNM, a subtype with no approved therapy" (6-K filing, 2026-08-17).
In the prespecified IMNM subtype analysis, patients treated with efgartigimod showed a 14.8-point greater improvement over placebo at 52 weeks, with scores of 45.05 versus 30.24 (p=0.0048). In the DM cohort, a clinically meaningful improvement of 14.5 points was observed (51.51 vs 36.96), though statistical significance was not reached (p=0.1093) in this smaller group (6-K filing, 2026-08-17).
Patient improvements were "observed early and sustained throughout study," with consistent treatment effects across both IMNM and DM subtypes (6-K filing, 2026-08-17). The treatment effect remained statistically significant from Week 4 through the full year, even with protocol-mandated steroid tapering (6-K filing, 2026-08-17).
Study Design and Market Context
The ALKIVIA study was a global, randomized, double-blind, placebo-controlled Phase 2/3 trial that enrolled 264 patients with active disease on background treatment (6-K filing, 2026-08-17). The Phase 3 portion enrolled 175 patients randomized 1:1 to receive weekly subcutaneous injections of efgartigimod or placebo (6-K filing, 2026-08-17).
According to the filing, approximately 100,000 people in the United States live with autoimmune myositis, including roughly 20,000 with IMNM and 40,000 with DM (6-K filing, 2026-08-17). Up to 80 percent of patients report long-term disability despite treatment, with current care relying primarily on corticosteroids and broad immunosuppressants (6-K filing, 2026-08-17).
The safety profile observed was consistent with prior studies and the known profile of efgartigimod (6-K filing, 2026-08-17). VYVGART is currently approved for generalized myasthenia gravis, while VYVGART Hytrulo is approved for gMG and chronic inflammatory demyelinating polyneuropathy (6-K filing, 2026-08-17).
Detailed results will be presented at an upcoming medical meeting, while the company continues evaluating efgartigimod in other autoimmune rheumatologic diseases including Sjögren's disease and systemic sclerosis (6-K filing, 2026-08-17).
This article was generated by MarginX from the 6-K filing on 2026-08-17. It is not investment advice.